Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederick G Hayden

Showing results (41-50 of 157) with videos related to

Pageof 16
Sort By:
The Journal of Infectious Diseases|May 10, 2002
Rhinovirus and coronavirus infection-associated hospitalizations among older adultsAnn R Falsey, Edward E Walsh, Frederick G Hayden
Antiviral Therapy|January 25, 2006
Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatmentLuis Barroso, John Treanor, Larisa Gubareva, et al.
The Journal of Infectious Diseases|November 26, 2002
Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in familiesLarisa V Gubareva, Dmitri V Novikov, Frederick G Hayden
European Journal of Internal Medicine|January 20, 2020
Comment to: Baloxavir efficacy in North American AdultsSimon Portsmouth, Keiko Kawaguchi, Takeki Uehara, et al.
Antiviral Research|June 28, 2019
Antivirals targeting the polymerase complex of influenza virusesEdin J Mifsud, Frederick G Hayden, Aeron C Hurt
Antimicrobial Agents and Chemotherapy|October 28, 2005
Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitorsVasiliy P Mishin, Frederick G Hayden, Larisa V Gubareva
The Lancet. Infectious Diseases|September 13, 2014
Antiviral combinations for severe influenzaJake Dunning, J Kenneth Baillie, Bin Cao, et al.
Influenza and Other Respiratory Viruses|June 17, 2026
Antiviral Resistance in Influenza: Clinical and Public Health ImplicationsJinghao Nicholas Ngiam, Matthew Chung Yi Koh, Frederick G Hayden
Pharmacoeconomics|April 12, 2006
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UKBeate Sander, Frederick G Hayden, Marlene Gyldmark, et al.
Lancet (London, England)|August 15, 2009
How to maintain surveillance for novel influenza A H1N1 when there are too many cases to countMarc Lipsitch, Frederick G Hayden, Benjamin J Cowling, et al.
Pageof 16

Showing results (41-50 of 157) with videos related to

Sort By:
Pageof 16
The Journal of Infectious Diseases|May 10, 2002
Rhinovirus and coronavirus infection-associated hospitalizations among older adultsAnn R Falsey, Edward E Walsh, Frederick G Hayden
Antiviral Therapy|January 25, 2006
Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatmentLuis Barroso, John Treanor, Larisa Gubareva, et al.
The Journal of Infectious Diseases|November 26, 2002
Assessment of hemagglutinin sequence heterogeneity during influenza virus transmission in familiesLarisa V Gubareva, Dmitri V Novikov, Frederick G Hayden
European Journal of Internal Medicine|January 20, 2020
Comment to: Baloxavir efficacy in North American AdultsSimon Portsmouth, Keiko Kawaguchi, Takeki Uehara, et al.
Antiviral Research|June 28, 2019
Antivirals targeting the polymerase complex of influenza virusesEdin J Mifsud, Frederick G Hayden, Aeron C Hurt
Antimicrobial Agents and Chemotherapy|October 28, 2005
Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitorsVasiliy P Mishin, Frederick G Hayden, Larisa V Gubareva
The Lancet. Infectious Diseases|September 13, 2014
Antiviral combinations for severe influenzaJake Dunning, J Kenneth Baillie, Bin Cao, et al.
Influenza and Other Respiratory Viruses|June 17, 2026
Antiviral Resistance in Influenza: Clinical and Public Health ImplicationsJinghao Nicholas Ngiam, Matthew Chung Yi Koh, Frederick G Hayden
Pharmacoeconomics|April 12, 2006
Post-exposure influenza prophylaxis with oseltamivir: cost effectiveness and cost utility in families in the UKBeate Sander, Frederick G Hayden, Marlene Gyldmark, et al.
Lancet (London, England)|August 15, 2009
How to maintain surveillance for novel influenza A H1N1 when there are too many cases to countMarc Lipsitch, Frederick G Hayden, Benjamin J Cowling, et al.
Pageof 16